Clinical Trial Update: Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Cediranib (RECENTIN) in combination with chemotherapy for untreated metastatic colorectal cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• RECENTIN (cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-10-30